Risankizumab was effective and well tolerated as induction therapy in patients with moderately to severely active Crohn’s disease, though there were no significant differences in efficacy between 600mg and 1200mg doses.

D’Haens, et al. report the results of ADVANCE and MOTIVATE, which were two Phase 3 induction trials investigating the safety and efficacy of risankizumab at 600mg and 1200mg doses. Coprimary endpoints were clinical remission and endoscopic response at Week 12.